

# Michael Hutchinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6546813/publications.pdf>

Version: 2024-02-01

216  
papers

22,299  
citations

41258

49  
h-index

8599

146  
g-index

217  
all docs

217  
docs citations

217  
times ranked

17528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
2	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 899-910.	13.9	2,916
3	Rate of Pregnancy-Related Relapse in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 1998, 339, 285-291.	13.9	1,403
4	Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1087-1097.	13.9	1,161
5	Pregnancy and multiple sclerosis (the PRIMIS study): clinical predictors of postpartum relapse. <i>Brain</i> , 2004, 127, 1353-1360.	3.7	573
6	Differential diagnosis of suspected multiple sclerosis: a consensus approach. <i>Multiple Sclerosis Journal</i> , 2008, 14, 1157-1174.	1.4	560
7	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology</i> , The, 2009, 8, 254-260.	4.9	430
8	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
9	PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY. <i>Neurology</i> , 2008, 71, 1291-1292.	1.5	324
10	The incidence and significance of anti-natalizumab antibodies. <i>Neurology</i> , 2007, 69, 1391-1403.	1.5	312
11	MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. <i>Neurology</i> , 2007, 68, 1390-1401.	1.5	307
12	Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. <i>Human Molecular Genetics</i> , 2000, 9, 637-644.	1.4	255
13	New perspectives in the natural history of multiple sclerosis. <i>Neurology</i> , 2010, 74, 2004-2015.	1.5	226
14	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009, 256, 405-415.	1.8	193
15	Health-related quality of life in multiple sclerosis: effects of natalizumab. <i>Annals of Neurology</i> , 2007, 62, 335-346.	2.8	172
16	REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. <i>Brain</i> , 2008, 131, 1078-1086.	3.7	163
17	Temporal Discrimination Threshold: VBM evidence for an endophenotype in adult onset primary torsion dystonia. <i>Brain</i> , 2009, 132, 2327-2335.	3.7	134
18	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134

#	ARTICLE	IF	CITATIONS
19	Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Multiple Sclerosis Journal, 2005, 11, 46-50.	1.4	128
20	Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain, 2009, 132, 1753-1763.	3.7	126
21	Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Multiple Sclerosis Journal, 2017, 23, 253-265.	1.4	126
22	Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology, 2007, 68, 1299-1304.	1.5	123
23	Unrecognised symptoms of depression in a community-based population with multiple sclerosis. Journal of Neurology, 2006, 253, 219-223.	1.8	93
24	Familial hemiplegic migraine and autosomal dominant arteriopathy with leukoencephalopathy (CADASIL). Annals of Neurology, 1995, 38, 817-824.	2.8	91
25	Natalizumab: A new treatment for relapsing remitting multiple sclerosis. Therapeutics and Clinical Risk Management, 2007, 3, 259-268.	0.9	90
26	Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology, 2004, 63, 1423-1426.	1.5	89
27	Assessing disability progression with the Multiple Sclerosis Functional Composite. Multiple Sclerosis Journal, 2009, 15, 984-997.	1.4	89
28	Leigh disease associated with a novel mitochondrial DNA ND5 mutation. European Journal of Human Genetics, 2002, 10, 141-144.	1.4	88
29	Does natalizumab therapy worsen neuromyelitis optica?. Neurology, 2012, 79, 1065-1066.	1.5	85
30	An epidemiological study of Wilson's disease in the Republic of Ireland.. Journal of Neurology, Neurosurgery and Psychiatry, 1993, 56, 298-300.	0.9	76
31	Temporal discrimination thresholds in adult-onset primary torsion dystonia: an analysis by task type and by dystonia phenotype. Journal of Neurology, 2012, 259, 77-82.	1.8	76
32	SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. Neurology, 2001, 56, 1230-1233.	1.5	71
33	Pharmacogenomics of responsiveness to interferon IFN- $\beta$ treatment in multiple sclerosis: A genetic screen of 100 type I interferon-inducible genes. Clinical Pharmacology and Therapeutics, 2005, 78, 635-635.	2.3	71
34	Interferon- $\beta$ 1b in the treatment of secondary progressive MS. Neurology, 2001, 57, 1870-1875.	1.5	70
35	Temporal discrimination, a cervical dystonia endophenotype: Penetrance and functional correlates. Movement Disorders, 2014, 29, 804-811.	2.2	70
36	Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current Medical Research and Opinion, 2014, 30, 613-627.	0.9	70

#	ARTICLE	IF	CITATIONS
37	Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 572-576.	0.9	68
38	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. <i>Journal of Neurology</i> , 2013, 260, 2286-2296.	1.8	68
39	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. <i>Journal of Neurology</i> , 2012, 259, 898-905.	1.8	66
40	The endophenotype and the phenotype: Temporal discrimination and adult-onset dystonia. <i>Movement Disorders</i> , 2013, 28, 1766-1774.	2.2	63
41	Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. <i>Neurology</i> , 2015, 84, 1145-1152.	1.5	63
42	The incidence of sudden unexpected death in epilepsy (sudep) in south dublin and wicklow. <i>Seizure: the Journal of the British Epilepsy Association</i> , 1998, 7, 355-358.	0.9	59
43	The prevalence of "pure" autosomal dominant hereditary spastic paraparesis in the island of Ireland. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 72, 43-46.	0.9	59
44	Epidemiological, clinical and genetic aspects of adult onset isolated focal dystonia in Ireland. <i>European Journal of Neurology</i> , 2017, 24, 73-81.	1.7	59
45	Neuroleptic malignant syndrome.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 271-273.	0.9	58
46	Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 317-322.	0.9	56
47	Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p. <i>Neurology</i> , 2000, 54, 1510-1517.	1.5	54
48	Cognitive dysfunction in early multiple sclerosis: a review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 359-364.	0.2	54
49	Sensory abnormalities in unaffected relatives in familial adult-onset dystonia. <i>Neurology</i> , 2005, 65, 938-940.	1.5	53
50	Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. <i>Brain</i> , 2011, 134, 2656-2663.	3.7	51
51	Genetic polymorphisms, their allele combinations and IFN- $\beta$ treatment response in Irish multiple sclerosis patients. <i>Pharmacogenomics</i> , 2009, 10, 1177-1186.	0.6	48
52	Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 103-118.	1.7	48
53	A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 521-525.	0.9	48
54	Further evidence of dementia in <i>SPG4</i> -linked autosomal dominant hereditary spastic paraplegia. <i>Neurology</i> , 2004, 62, 407-410.	1.5	47

#	ARTICLE	IF	CITATIONS
55	A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1797-1800.	1.4	46
56	Temporal Discrimination: Mechanisms and Relevance to Adult-Onset Dystonia. <i>Frontiers in Neurology</i> , 2017, 8, 625.	1.1	46
57	A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0127960.	1.1	45
58	2017 McDonald diagnostic criteria: A review of the evidence. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 48-54.	0.9	44
59	Phenotype of AD-HSP due to mutations in the <i>SPAST</i> gene. <i>Neurology</i> , 2000, 55, 1794-1800.	1.5	43
60	Neural correlates of abnormal sensory discrimination in laryngeal dystonia. <i>NeuroImage: Clinical</i> , 2016, 10, 18-26.	1.4	43
61	Cervical Dystonia: A Disorder of the Midbrain Network for Covert Attentional Orienting. <i>Frontiers in Neurology</i> , 2014, 5, 54.	1.1	42
62	Patient-centered outcomes. <i>Neurology</i> , 2010, 74, S24-35.	1.5	41
63	Bipolar affective disorder prior to the onset of multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 1993, 88, 388-393.	1.0	40
64	Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 253-257.	1.4	40
65	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, genetic homogeneity, and mapping of the locus within a 2-cM interval. <i>American Journal of Human Genetics</i> , 1996, 58, 171-81.	2.6	40
66	Molding the sensory cortex: Spatial acuity improves after botulinum toxin treatment for cervical dystonia. <i>Movement Disorders</i> , 2007, 22, 2443-2446.	2.2	39
67	CADASIL imitating multiple sclerosis: the importance of MRI markers. <i>Multiple Sclerosis Journal</i> , 2002, 8, 430-432.	1.4	38
68	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy: MR findings. <i>American Journal of Neuroradiology</i> , 1995, 16, 2115-9.	1.2	38
69	Cervical dystonia following peripheral trauma. <i>Journal of Neurology</i> , 2004, 251, 150-155.	1.8	37
70	Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 980-983.	0.9	37
71	Economic costs associated with an MS relapse. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 678-683.	0.9	36
72	Paroxysmal torticollis and blepharospasm following bilateral cerebellar Infarction. <i>Journal of Neurology</i> , 2006, 253, 1644-1645.	1.8	35

#	ARTICLE	IF	CITATIONS
73	Comparing endophenotypes in adult-onset primary torsion dystonia. <i>Movement Disorders</i> , 2010, 25, 84-90.	2.2	35
74	Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2145-2156.	0.9	34
75	Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 513-519.	0.9	34
76	Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance. <i>European Journal of Human Genetics</i> , 1998, 6, 275-282.	1.4	32
77	Predicting beta-interferon failure in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007, 13, 336-342.	1.4	32
78	<i>OAS1</i> . <i>Neurology</i> , 2010, 75, 411-418.	1.5	31
79	A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls. <i>Clinical Neurophysiology</i> , 2010, 121, 1420-1426.	0.7	31
80	Pallidal stimulation for cervical dystonia does not correct abnormal temporal discrimination. <i>Movement Disorders</i> , 2013, 28, 1874-1877.	2.2	30
81	Pregnancy in multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 1043-1045.	0.9	29
82	Machine Learning EEG to Predict Cognitive Functioning and Processing Speed Over a 2-Year Period in Multiple Sclerosis Patients and Controls. <i>Brain Topography</i> , 2018, 31, 346-363.	0.8	29
83	A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1095-1100.	1.4	26
84	Unmet needs of multiple sclerosis patients in the community. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 144-150.	0.9	26
85	New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 867-870.	1.4	26
86	Inherited myoclonus-dystonia and epilepsy: Further evidence of an association?. <i>Movement Disorders</i> , 2004, 19, 1456-1459.	2.2	25
87	A 10-year follow-up of the European multicenter trial of interferon $\beta$ -1b in secondary-progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 533-543.	1.4	24
88	Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1528-1531.	1.4	23
89	Using atypical symptoms and red flags to identify non-demyelinating disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 44-48.	0.9	23
90	Incidence of multiple sclerosis in the Republic of Ireland: A prospective population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 13, 75-80.	0.9	22

#	ARTICLE	IF	CITATIONS
91	Disrupted superior collicular activity may reveal cervical dystonia disease pathomechanisms. <i>Scientific Reports</i> , 2017, 7, 16753.	1.6	22
92	The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101863.	0.9	22
93	An evaluation of the role of environmental factors in the disease penetrance of cervical dystonia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 331-335.	0.9	21
94	Sun exposure is an environmental factor for the development of blepharospasm. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 420-424.	0.9	20
95	Only Low Frequency Event-Related EEG Activity Is Compromised in Multiple Sclerosis: Insights from an Independent Component Clustering Analysis. <i>PLoS ONE</i> , 2012, 7, e45536.	1.1	19
96	The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006, 12, 599-604.	1.4	18
97	Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double-blind placebo-controlled trial. <i>Trials</i> , 2013, 14, 272.	0.7	18
98	Symptom overlap in anxiety and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1349-1354.	1.4	18
99	Epidemiology of Wilson's disease in Ireland. <i>Movement Disorders</i> , 2014, 29, 1567-1568.	2.2	18
100	Age-Related Sexual Dimorphism in Temporal Discrimination and in Adult-Onset Dystonia Suggests GABAergic Mechanisms. <i>Frontiers in Neurology</i> , 2015, 6, 258.	1.1	18
101	Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2011, 18, 792-795.	1.7	17
102	Neurodegeneration in multiple sclerosis is a process separate from inflammation: No. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1628-1631.	1.4	17
103	Effects of vitamin D <sup>3</sup> in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731772729.	0.5	17
104	Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T <i>POLG</i> mutation. <i>Muscle and Nerve</i> , 2010, 41, 265-269.	1.0	16
105	Truly benign multiple sclerosis is rare: let's stop fooling ourselves - Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 15-15.	1.4	16
106	Dexterity Training Improves Manual Precision in Patients Affected by Essential Tremor. <i>Archives of Physical Medicine and Rehabilitation</i> , 2014, 95, 705-710.	0.5	16
107	Natalizumab improves ambulation in relapsing~remitting multiple sclerosis: results from the prospective <scp>TIMER</scp> study and a retrospective analysis of <scp>AFFIRM</scp>. <i>European Journal of Neurology</i> , 2015, 22, 570-577.	1.7	16
108	Trust the Patient Not the Doctor: The Determinants of Quality of Life in Cervical Dystonia. <i>Frontiers in Neurology</i> , 2020, 11, 991.	1.1	16

#	ARTICLE	IF	CITATIONS
109	Social cognition in cervical dystonia: A case-control study. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2020, 3, 100072.	0.5	15
110	Non-motor features of cervical dystonia: Cognition, social cognition, psychological distress and quality of life. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 4, 100084.	0.5	15
111	The functional limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. <i>Journal of Neurology</i> , 1995, 242, 650-657.	1.8	14
112	Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients. <i>Journal of the Neurological Sciences</i> , 2011, 305, 45-52.	0.3	14
113	Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. <i>Journal of Neurology</i> , 2005, 252, 1245-1248.	1.8	13
114	Predicting and preventing the future: actively managing multiple sclerosis. <i>Practical Neurology</i> , 2009, 9, 133-143.	0.5	13
115	A budget impact analysis of natalizumab use in Ireland. <i>Irish Journal of Medical Science</i> , 2012, 181, 199-204.	0.8	13
116	Young Women do it Better: Sexual Dimorphism in Temporal Discrimination. <i>Frontiers in Neurology</i> , 2015, 6, 160.	1.1	13
117	The premotor syndrome of cervical dystonia: Disordered processing of salient environmental stimuli. <i>Movement Disorders</i> , 2018, 33, 232-237.	2.2	13
118	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 591-600.	1.4	13
119	Delayed P100-Like Latencies in Multiple Sclerosis: A Preliminary Investigation Using Visual Evoked Spread Spectrum Analysis. <i>PLoS ONE</i> , 2016, 11, e0146084.	1.1	13
120	Neuropsychological assessment in multiple sclerosis: methodological issues and concerns. <i>Multiple Sclerosis Journal</i> , 1996, 2, 57-65.	1.4	12
121	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	1.7	12
122	Linkage to a known gene but no mutation identified: comprehensive reanalysis of SPG4 HSP pedigrees reveals large deletions as the sole cause. <i>Human Mutation</i> , 2007, 28, 739-740.	1.1	10
123	Outcome of beta-interferon treatment in relapsing-remitting multiple sclerosis: a Bayesian analysis. <i>Journal of Neurology</i> , 2007, 254, 1547-1554.	1.8	10
124	One can prevent post-partum MS relapses by exclusive breast feeding: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1569-1570.	1.4	10
125	A novel <i>CACNA1A</i> mutation associated with adult-onset, paroxysmal head tremor. <i>Movement Disorders</i> , 2013, 28, 842-843.	2.2	10
126	Application of virtual reality head mounted display for investigation of movement: a novel effect of orientation of attention. <i>Journal of Neural Engineering</i> , 2016, 13, 056006.	1.8	10



#	ARTICLE	IF	CITATIONS
127	Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe. <i>Frontiers in Neurology</i> , 2021, 12, 646841.	1.1	10
128	Safety first, efficacy second in disease modifying therapies. <i>Multiple Sclerosis Journal</i> , 2011, 17, 380-381.	1.4	9
129	Mood disorder affects age at onset of adult-onset cervical dystonia. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2020, 3, 100049.	0.5	9
130	We Must Talk about Sex and Focal Dystonia. <i>Movement Disorders</i> , 2021, 36, 604-608.	2.2	9
131	Spontaneous intracranial hypotension: case reports and literature review. <i>Irish Journal of Medical Science</i> , 2012, 181, 171-177.	0.8	8
132	Perceived and objective cognitive impairment in newly diagnosed versus established multiple sclerosis: impact of disease duration. <i>Irish Journal of Medical Science</i> , 2021, 190, 1149-1154.	0.8	8
133	Adult onset dystonia: A disorder of the collicularâ€“pulvinarâ€“amygdala network. <i>Cortex</i> , 2021, 143, 282-289.	1.1	8
134	Wilson's disease and the neuroleptic malignant syndrome. <i>Irish Journal of Psychological Medicine</i> , 1990, 7, 138-139.	0.7	7
135	The major cause of multiple sclerosis is environmental: genetics has a minor role - Commentary. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1176-1176.	1.4	7
136	There is no such thing as a mild MS relapse. The mild relapse is an Anglo-Saxon delusion - Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 930-931.	1.4	7
137	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald Criteria 2010: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 719-720.	1.4	7
138	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1690-1691.	1.4	7
139	Relapses do not matter in relation to long-term disability: Commentary. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1417-1417.	1.4	6
140	Evoked potentials are of little use in the diagnosis or monitoring of MS: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1824-1825.	1.4	6
141	Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1302-1303.	1.4	6
142	A comparison of stimulus presentation methods in temporal discrimination testing. <i>Physiological Measurement</i> , 2017, 38, N57-N64.	1.2	6
143	Practice does not make perfect: Temporal discrimination in musicians with and without dystonia. <i>Movement Disorders</i> , 2017, 32, 1791-1792.	2.2	6
144	A novel GNAL mutation in familial dystonia presenting with childhood tremor and myoclonus. <i>Movement Disorders</i> , 2019, 34, 923-924.	2.2	6

#	ARTICLE	IF	CITATIONS
145	In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 29-30.	1.4	5
146	Non-parametric bootstrapping method for measuring the temporal discrimination threshold for movement disorders. <i>Journal of Neural Engineering</i> , 2015, 12, 046026.	1.8	5
147	Temporal discrimination threshold and blink reflex recovery cycle in cervical dystonia – two sides of the same coin?. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 4-7.	1.1	5
148	A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene. <i>Neurobiology of Aging</i> , 2021, 106, 343.e1-343.e8.	1.5	5
149	Phenotypic diversity associated with the mitochondrial m.8313G>A point mutation. <i>Muscle and Nerve</i> , 2009, 40, 648-651.	1.0	4
150	Clinically isolated syndrome: a protected zone for trials of new therapies?. <i>Multiple Sclerosis Journal</i> , 2010, 16, 754-755.	1.4	4
151	Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 396-397.	1.4	4
152	Multiparity in women with multiple sclerosis causes less long-term disability: Commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1437-1438.	1.4	4
153	A useful annual review of cognition in relapsing MS is beyond most neurologists – Commentary. <i>Multiple Sclerosis Journal</i> , 2016, 22, 730-732.	1.4	4
154	Immediate thrombocytopenia at time of alemtuzumab infusion for multiple sclerosis – Not always self-limiting, fully reversible or predictable. <i>Multiple Sclerosis Journal</i> , 2018, 24, 552-553.	1.4	4
155	Slowed Luminance Reaction Times in Cervical Dystonia: Disordered Superior Colliculus Processing. <i>Movement Disorders</i> , 2020, 35, 877-880.	2.2	4
156	Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study. <i>Journal of Sleep Research</i> , 2021, 30, e13159.	1.7	4
157	Longitudinal Follow-Up of Mood in Cervical Dystonia and Influence on Age at Onset. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 614-618.	0.8	4
158	Natalizumab Therapy of Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 787-789.	0.5	3
159	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1533-1533.	1.4	3
160	DOES JCV ANTIBODY POSITIVITY ENCOURAGE CESSATION OF NATALIZUMAB THERAPY IN MULTIPLE SCLEROSIS?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.92-e2.	0.9	3
161	Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1694-1695.	1.4	3
162	Funding CCSVI research is/was a waste of valuable time, money and intellectual energy: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 861-862.	1.4	3

#	ARTICLE	IF	CITATIONS
163	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1242-1243.	1.4	3
164	Neural Correlates of Abnormal Temporal Discrimination in Unaffected Relatives of Cervical Dystonia Patients. <i>Frontiers in Integrative Neuroscience</i> , 2019, 13, 8.	1.0	3
165	A Study of the Midbrain Network for Covert Attentional Orienting in Cervical Dystonia Patients using Dynamic Causal Modelling. , 2019, 2019, 3519-3522.		3
166	A headset method for measuring the visual temporal discrimination threshold in cervical dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2014, 4, 249.	1.1	3
167	Reduced Frequency of Ipsilateral Express Saccades in Cervical Dystonia: Probing the Nigro-Tectal Pathway. <i>Tremor and Other Hyperkinetic Movements</i> , 2018, 8, 592.	1.1	3
168	PONM12 Multifocal motor neuropathy due to infliximab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, e63-e63.	0.9	2
169	Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1382-1383.	1.4	2
170	Deaths and disability from natalizumab are no longer tolerable: Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1073-1073.	1.4	2
171	If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 143-144.	1.4	2
172	The best basic science paper in multiple sclerosis in 2013: Disease specific molecular events in cortical multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1817-1818.	1.4	2
173	The best basic science paper in multiple sclerosis in 2014: Citicoline, remyelination and neuroprotection: Commentary. <i>Multiple Sclerosis Journal</i> , 2015, 21, 374-375.	1.4	2
174	Symptomatic therapy in multiple sclerosis: Big pharma should do more “ commentary. <i>Multiple Sclerosis Journal</i> , 2015, 21, 982-983.	1.4	2
175	All relapsing multiple sclerosis patients should be managed at a specialist clinic “ Commentary. <i>Multiple Sclerosis Journal</i> , 2016, 22, 876-877.	1.4	2
176	Menstrual cycle and the temporal discrimination threshold. <i>Physiological Measurement</i> , 2017, 38, N65-N72.	1.2	2
177	Measurement & Analysis of the Temporal Discrimination Threshold Applied to Cervical Dystonia. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	2
178	Response to “isolated head tremor: A DAT SPECT and somatosensory temporal discrimination study.” <i>Parkinsonism and Related Disorders</i> , 2021, 87, 166-167.	1.1	2
179	Reliability of DNMSQuest as a Screening Tool for Mood Disorders in Cervical Dystonia. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 925-931.	0.8	2
180	A Headset Method for Measuring the Visual Temporal Discrimination Threshold in Cervical Dystonia. <i>Tremor and Other Hyperkinetic Movements</i> , 2020, 4, 249.	1.1	2

#	ARTICLE	IF	CITATIONS
181	Intravenous therapy for the treatment of multiple sclerosis. <i>Future Prescriber</i> , 2008, 8, 15-20.	0.1	1
182	Cervical dystonia presenting as a phenocopy in an Irish SCA2 family. <i>Movement Disorders</i> , 2009, 24, 466-467.	2.2	1
183	Obituary. <i>Multiple Sclerosis Journal</i> , 2010, 16, 518-519.	1.4	1
184	We are about to cure MS in the next 10 years, even though we do not know its cause: Commentary. <i>Multiple Sclerosis Journal</i> , 2012, 18, 786-787.	1.4	1
185	The best clinical paper on multiple sclerosis in 2012: Commentary. <i>Multiple Sclerosis Journal</i> , 2013, 19, 522-523.	1.4	1
186	Response to comment on the article by Allen et al. "A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers". <i>Multiple Sclerosis Journal</i> , 2013, 19, 509-509.	1.4	1
187	Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1169-1170.	1.4	1
188	MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary. <i>Multiple Sclerosis Journal</i> , 2014, 20, 284-285.	1.4	1
189	Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1374-1375.	1.4	1
190	Any evident MRI T2 lesion activity should guide change of therapy in multiple sclerosis - Commentary. <i>Multiple Sclerosis Journal</i> , 2015, 21, 136-137.	1.4	1
191	Exploring the unknown: electrophysiological and behavioural measures of visuospatial learning. <i>European Journal of Neuroscience</i> , 2016, 43, 1128-1136.	1.2	1
192	Irish neurological association. <i>Irish Journal of Medical Science</i> , 1984, 153, 152-157.	0.8	0
193	Royal academy of medicine in Ireland section of medicine. <i>Irish Journal of Medical Science</i> , 1985, 154, 477-482.	0.8	0
194	Irish Neurological association. <i>Irish Journal of Medical Science</i> , 1990, 159, 190-194.	0.8	0
195	Royal Academy of Medicine in Ireland Section of Pathology. <i>Irish Journal of Medical Science</i> , 1997, 166, 267-269.	0.8	0
196	POMD05 Temporal discrimination threshold in patients with sporadic adult-onset primary torsion dystonia and their first degree relatives. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, e58-e58.	0.9	0
197	PAW29 Multiple sclerosis in Ireland: regional variation in prevalence and vitamin D status. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, e31-e31.	0.9	0
198	Controversies in multiple sclerosis: a series of debates. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1170-1170.	1.4	0

#	ARTICLE	IF	CITATIONS
199	The neurologist's dilemma: MS is a grey matter disease that standard clinical and MRI measures cannot assess adequately – Commentary. Multiple Sclerosis Journal, 2012, 18, 561-562.	1.4	0
200	In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! – Commentary. Multiple Sclerosis Journal, 2012, 18, 269-270.	1.4	0
201	040 – Electronic neurology referrals: a solution for an overburdened healthcare system?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.205-e1.	0.9	0
202	Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Commentary. Multiple Sclerosis Journal, 2012, 18, 1213-1214.	1.4	0
203	The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Commentary. Multiple Sclerosis Journal, 2012, 18, 1684-1685.	1.4	0
204	THE COST OF A MULTIPLE SCLEROSIS RELAPSE. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A18.3-A18.	0.9	0
205	The best basic science paper on multiple sclerosis in 2012: Commentary. Multiple Sclerosis Journal, 2013, 19, 1130-1131.	1.4	0
206	Electrophysiological and behavioral measures of visuo-motor learning for application in movement disorders. , 2014, 2014, 3533-6.		0
207	We can compare the relative efficacy multiple sclerosis medications by examining the results of independent clinical trials: Commentary. Multiple Sclerosis Journal, 2015, 21, 39-40.	1.4	0
208	The best clinical paper on multiple sclerosis in 2014: Herodotus and Chataway – Commentary. Multiple Sclerosis Journal, 2015, 21, 856-857.	1.4	0
209	Integrated multidisciplinary clinics should be the gold standard in managing progressive MS – Commentary. Multiple Sclerosis Journal, 2016, 22, 1130-1131.	1.4	0
210	Modeling the course and outcomes of MS is statistical twaddle – Commentary. Multiple Sclerosis Journal, 2016, 22, 144-145.	1.4	0
211	Marta Elian: Obituary. Multiple Sclerosis Journal, 2017, 23, 370-371.	1.4	0
212	Trials of Licenced RRMS DMTs in Progressive MS. , 2018, , 207-232.		0
213	Characterizing Brain Network Topology in Cervical Dystonia Patients and Unaffected Relatives via Graph Theory. , 2019, 2019, 1694-1697.		0
214	Update: Atypical presentation of a midgut neuroendocrine tumor originally diagnosed as eosinophilic fasciitis. Neurology, 2020, 95, 695-697.	1.5	0
215	Stress and Dystonia. Movement Disorders, 2021, 36, 1794-1794.	2.2	0
216	Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies. , 2013, , 187-219.		0